NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Retrophin, Inc. (“Retrophin” or the “Company”) (NasdaqGM:RTRX) securities between March 27, 2014 and September 30, 2014.
For more information, click here: http://zlk.9nl.com/retrophin-rtrx.
The Complaint alleges that defendants made materially false and misleading statements and/or omitted material information including: (a) that the Company’s founder and CEO was committing stock-trading irregularities and other violations of the Company’s Compensation Plan and other securities rules; (b) said irregularities included grants of shares in violation of the Company’s Incentive Compensation Plan and the failure to disclose stock grants to employees; and (c) as a result of the above, the Company’s financial statements were materially false and misleading at all relevant times.
On September 16, 2014, the Company announced that its CFO’s employment would be terminated effective February 28, 2015. Then on September 30, 2014, the Company announced its CEO was terminated and an interim CEO appointed, effective immediately.
If you suffered a loss in Retrophin you have until December 19, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/retrophin-rtrx.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.